Travere Book Value Per Share from 2010 to 2025

TVTX Stock

USD 20.37 0.64 3.05%

Travere Therapeutics Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share will likely drop to 0.71 in 2025. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Travere Therapeutics according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

0.74886365

Current Value

0.71

Quarterly Volatility

3.75088295

Credit Downgrade

Yuan Drop

Covid

Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 16.1 M, Selling General Administrative of 277.3 M or Other Operating Expenses of 584.9 M, as well as many indicators such as Price To Sales Ratio of 6.84, Dividend Yield of 0.0 or PTB Ratio of 22.1. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.

Check out the analysis of Travere Therapeutics Correlation against competitors.

For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Latest Travere Therapeutics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Travere Therapeutics over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Travere Therapeutics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0.68 X

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Travere Book Value Per Share Regression Statistics

	Arithmetic Mean	3.00
	Coefficient Of Variation	125.18
	Mean Deviation	3.30
	Median	2.70
	Standard Deviation	3.75
	Sample Variance	14.07
	Range	10.4258
	R-Value	0.19
	Mean Square Error	14.55
	R-Squared	0.03
	Significance	0.49
	Slope	0.15
	Total Sum of Squares	211.04

Travere Book Value Per Share History

	2025	0.71
	2024	0.75
	2023	2.7
	2022	0.67
	2021	5.05
	2020	4.44
	2019	5.22

Other Fundumenentals of Travere Therapeutics

Tangible Book Value Per Share

Travere Therapeutics Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Intangible Assets	Short Term Investments	Net Receivables	Good Will	Net Tangible Assets	Long Term Debt	Net Invested Capital	Net Working Capital	Property Plant Equipment	Short Long Term Debt	Capital Stock	Long Term Debt Total	Capital Surpluse
Total Assets		0.74	0.56	-0.61	0.72	0.91	0.99	0.19	0.76	0.15	0.84	0.96	0.4	-0.32	-0.39	0.72	0.73	0.68	0.36	0.66	0.49	-0.1	0.5
Total Stockholder Equity	0.74		-0.11	0.01	0.33	0.4	0.7	-0.09	0.28	0.54	0.81	0.6	0.57	0.14	0.23	0.1	0.35	0.4	0.11	0.12	-0.08	0.22	-0.08
Net Debt	0.56	-0.11		-0.94	0.67	0.79	0.6	0.49	0.83	-0.46	0.24	0.7	-0.01	-0.82	-0.92	0.94	0.71	0.53	0.36	0.78	0.84	-0.59	0.84
Retained Earnings	-0.61	0.01	-0.94		-0.69	-0.8	-0.65	-0.57	-0.92	0.42	-0.3	-0.72	-0.02	0.83	0.86	-0.9	-0.71	-0.52	-0.44	-0.83	-0.93	0.66	-0.93
Accounts Payable	0.72	0.33	0.67	-0.69		0.79	0.76	0.16	0.69	-0.2	0.43	0.8	0.08	-0.59	-0.65	0.75	0.63	0.52	0.21	0.74	0.62	-0.14	0.58
Total Liab	0.91	0.4	0.79	-0.8	0.79		0.92	0.25	0.82	-0.12	0.63	0.94	0.18	-0.47	-0.64	0.91	0.75	0.65	0.41	0.84	0.71	-0.18	0.71
Total Current Assets	0.99	0.7	0.6	-0.65	0.76	0.92		0.14	0.76	0.06	0.77	0.99	0.32	-0.37	-0.42	0.78	0.79	0.74	0.37	0.71	0.54	-0.1	0.55
Short Term Debt	0.19	-0.09	0.49	-0.57	0.16	0.25	0.14		0.67	0.07	0.29	0.17	0.18	-0.62	-0.46	0.25	0.2	-0.08	0.02	0.16	0.55	-0.84	0.53
Common Stock	0.76	0.28	0.83	-0.92	0.69	0.82	0.76	0.67		-0.11	0.59	0.79	0.29	-0.76	-0.73	0.79	0.69	0.5	0.42	0.72	0.82	-0.66	0.82
Current Deferred Revenue	0.15	0.54	-0.46	0.42	-0.2	-0.12	0.06	0.07	-0.11		0.48	-0.03	0.42	0.36	0.45	-0.42	-0.22	-0.17	-0.39	-0.58	-0.42	0.29	-0.37
Intangible Assets	0.84	0.81	0.24	-0.3	0.43	0.63	0.77	0.29	0.59	0.48		0.71	0.54	-0.06	-0.11	0.34	0.39	0.4	0.23	0.3	0.12	-0.08	0.14
Short Term Investments	0.96	0.6	0.7	-0.72	0.8	0.94	0.99	0.17	0.79	-0.03	0.71		0.26	-0.48	-0.54	0.85	0.84	0.77	0.35	0.74	0.59	-0.18	0.61
Net Receivables	0.4	0.57	-0.01	-0.02	0.08	0.18	0.32	0.18	0.29	0.42	0.54	0.26		-0.02	-0.03	-0.03	-0.08	-0.12	0.15	0.02	0.04	-0.03	-0.02
Good Will	-0.32	0.14	-0.82	0.83	-0.59	-0.47	-0.37	-0.62	-0.76	0.36	-0.06	-0.48	-0.02		0.84	-0.66	-0.6	-0.37	-0.19	-0.49	-0.78	0.77	-0.75
Net Tangible Assets	-0.39	0.23	-0.92	0.86	-0.65	-0.64	-0.42	-0.46	-0.73	0.45	-0.11	-0.54	-0.03	0.84		-0.81	-0.46	-0.26	-0.29	-0.66	-0.8	0.57	-0.77
Long Term Debt	0.72	0.1	0.94	-0.9	0.75	0.91	0.78	0.25	0.79	-0.42	0.34	0.85	-0.03	-0.66	-0.81		0.81	0.69	0.44	0.88	0.8	-0.36	0.81
Net Invested Capital	0.73	0.35	0.71	-0.71	0.63	0.75	0.79	0.2	0.69	-0.22	0.39	0.84	-0.08	-0.6	-0.46	0.81		0.91	0.33	0.63	0.59	-0.32	0.62
Net Working Capital	0.68	0.4	0.53	-0.52	0.52	0.65	0.74	-0.08	0.5	-0.17	0.4	0.77	-0.12	-0.37	-0.26	0.69	0.91		0.3	0.54	0.33	-0.11	0.43
Property Plant Equipment	0.36	0.11	0.36	-0.44	0.21	0.41	0.37	0.02	0.42	-0.39	0.23	0.35	0.15	-0.19	-0.29	0.44	0.33	0.3		0.58	0.38	-0.18	0.24
Short Long Term Debt	0.66	0.12	0.78	-0.83	0.74	0.84	0.71	0.16	0.72	-0.58	0.3	0.74	0.02	-0.49	-0.66	0.88	0.63	0.54	0.58		0.78	-0.27	0.74
Capital Stock	0.49	-0.08	0.84	-0.93	0.62	0.71	0.54	0.55	0.82	-0.42	0.12	0.59	0.04	-0.78	-0.8	0.8	0.59	0.33	0.38	0.78		-0.57	0.96
Long Term Debt Total	-0.1	0.22	-0.59	0.66	-0.14	-0.18	-0.1	-0.84	-0.66	0.29	-0.08	-0.18	-0.03	0.77	0.57	-0.36	-0.32	-0.11	-0.18	-0.27	-0.57		-0.58
Capital Surpluse	0.5	-0.08	0.84	-0.93	0.58	0.71	0.55	0.53	0.82	-0.37	0.14	0.61	-0.02	-0.75	-0.77	0.81	0.62	0.43	0.24	0.74	0.96	-0.58

Click cells to compare fundamentals

About Travere Therapeutics Financial Statements

Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	0.75	0.71
Tangible Book Value Per Share	(0.57)	(0.54)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC